Andrea Necchi, Rodryg Ramlau, Alejandro Falcón González, Arvind Chaudhry, Tilman Todenhöfer, Rana Tahbaz, Elisa Fontana, Patrizia Giannatempo, Jean-Laurent Deville, Damien Pouessel, Shinkyo Yoon, Thomas Powles, Mathieu Bernat, Manuel Häckl, Michalina Marszewska, Phil McKernan, Mikael Saulay, Federica Scaleia, Marc Engelhardt, Yohann Loriot, Arlene Siefker-Radtke, Maria De Santis
BACKGROUND: This Phase 1 b/2 study assessed the efficacy, in terms of objective response rate (ORR) of the FGFR1/2/3 kinase inhibitor derazantinib as monotherapy or in combination with atezolizumab in patients with metastatic urothelial cancer (mUC) and FGFR1-3 genetic aberrations (FGFR1-3GA). METHODS: This multicenter, open-label study comprised 5 substudies. In Substudies 1 and 5, patients with mUC with FGFR1-3GA received derazantinib monotherapy (300 mg QD in Substudy 1, 200 mg BID in Substudy 5)...
April 16, 2024: JNCI Cancer Spectrum